Compounds > 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and nad

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with nad in 1 studies

Compound Research Comparison

Studies
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Trials
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Recent Studies (post-2010)
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Studies
(nad)		Trials
(nad)		Recent Studies (post-2010) (nad)
330403330,121885,663

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abdo, WF; Bloem, BR; De Jong, D; Hendriks, JC; Horstink, MW; Kremer, BP; Verbeek, MM1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and nad

ArticleYear
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Adult; Aged; Benzamides; Brain; Diagnosis, Differential; Electromyography; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Iodine Radioisotopes; Lactic Acid; Male; Methoxyhydroxyphenylglycol; Multiple System Atrophy; NAD; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2004